Alvotech Announces $125M Public Offering & Private Placement

Alvotech has announced the commencement of an underwritten public offering of its ordinary shares, alongside a concurrent private placement to certain professional clients in the European Economic Area. The company expects to raise approximately $125 million in gross proceeds from these combined offerings. The capital raised is intended to fund the continued development of its biosimilar assets, as well as for working capital and general corporate purposes, including intellectual property protection, commercial expenditures, and potential acquisitions.